AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15110902
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of slow-release indapamide SR
Trial: 2522134
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of amlodipine
Trial: 15110902
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg of slow-release indapamide SR + 4 mg of perindopril
Trial: 15110902
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of amlodipine + 4 mg of perindopril
Trial: 11244764
Drug: dopamine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dopamine 2 mcg.kg‐1.min‐1
Trial: 11244764
Drug: dobutamine 2
RxNorm normalized name: dobutamine 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dobutamine 2 mcg.kg‐1.min‐1
Trial: 8065152
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 20 mg and 10 mg of mitomycin C IV on postoperative days 0 and 1, then tegafur at 600 mg/body daily PO from postoperative week 2 for 1 year.
Trial: 8065152
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 0.2 mg of mitomycin C per kg IV at 3, 6, 9, and 12 months after surgery.
Trial: 3338348
Drug: Conventional intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intramuscular (IM) analgesia
Trial: 22446638
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg MF59(®) adjuvanted vaccine
Trial: 22446638
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg MF59(®) adjuvanted vaccine
Trial: 22446638
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg non-adjuvanted vaccine
Trial: 22446638
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg MF59(®) adjuvanted vaccine (adults)
Trial: 22446638
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg MF59(®) adjuvanted vaccine (elderly)
Trial: 22446638
Drug: Booster administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Booster administration after two priming doses
Trial: 20033465
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of MenACWY-CRM at 6 and 12 months
Trial: 20033465
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of MenACWY-CRM at 12 months
Trial: 20033465
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of MenC at 12 months
Trial: 20033465
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of MenACWY-CRM
Trial: 20033465
Drug: MenACWY-CRM (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM (two doses)
Trial: 20033465
Drug: MenC (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenC (one dose)
Trial: 15221207
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 microg capsules daily)
Trial: 19583878
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one capsule daily)
Trial: 1827019
Drug: Isradipine 5
RxNorm normalized name: isradipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 5 mg once daily
Trial: 8061848
Drug: Spirapril 6
RxNorm normalized name: spirapril 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 6 mg once daily
Trial: 2455089
Drug: Pharmacological protection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological protection with coenzyme Q (5 mg/kg) and aprotinin (10,000 KIU/kg) administered intravenously every 12 hours post-surgery and a single dose intraoperatively.
Trial: 30285125
Drug: β2-agonist terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β2-agonist terbutaline (0.2 to 0.4 mg)
Trial: 29066444
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 200,000 IU followed by monthly 100,000 IU doses (n=71)
Trial: 29066444
Drug: Placebo monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo monthly (n=79)
Trial: 24377531
Drug: Goshajinkigan (GJG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goshajinkigan (GJG) 7.5 g/day
Trial: 24377531
Drug: Mecobalamin (B12)
RxNorm normalized name: mecobalamin / vitamin B12
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mecobalamin (B12) 1500 μg/day
Trial: 25511923
Drug: Erlotinib maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib maintenance therapy
Trial: 21919119
Drug: Emotionally Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotionally Focused Therapy (EFT)
Trial: 10037386
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy transurethral microwave therapy
Trial: 8625038
Drug: Methyl‐lomustine/5‐FU/Leucovorin (MFL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl‐lomustine/5‐FU/Leucovorin (MFL) regimen (methyl‐lomustine 110 mg/m2 on Day 1 of each 8-week cycle, 5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Trial: 8625038
Drug: 5‐FU and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU and Leucovorin (FL) regimen (5‐FU 600 mg/m2 weekly, Leucovorin 500 mg/m2 weekly)
Trial: 2158151
Drug: Heparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5,000 IU b.i.d.)
Trial: 31780589
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with antipsychotic medication
Trial: 24125620
Drug: Levocarnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine (3 g within 250 ml normal saline for intravenous infusion)
Trial: 24125620
Drug: Conventional anti‐heart
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anti‐heart failure drugs
Trial: 29365058
Drug: 6-monthly 18FDG-PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-monthly 18FDG-PET/CT
Trial: 24041270
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (405 mg/4 weeks, 300 mg/2 weeks, 150 mg/2 weeks)
Trial: 24041270
Drug: Sub-therapeutic olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-therapeutic olanzapine long-acting injection (45 mg/4 weeks)
Trial: 8883119
Drug: salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmon calcitonin nasal spray (CT; 200 IU/day, 1 month on and 1 month off) and calcium (500 mg/day)
Trial: 8883119
Drug: calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium (500 mg/day)
Trial: 3917316
Drug: Natural progesterone
RxNorm normalized name: NATURAL PROGESTERONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural progesterone given by mouth in increasing doses
Trial: 27029823
Drug: Venetoclax 50
RxNorm normalized name: venetoclax 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 50 mg (uncoated tablet)
Trial: 27029823
Drug: Venetoclax film-coated
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax film-coated 100 mg tablet after low-fat breakfast
Trial: 27029823
Drug: Venetoclax film-coated
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax film-coated 100 mg tablet after high-fat breakfast
Trial: 12218282
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D
Trial: 10589753
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m2, i.v., over a 3-h period, escalated to 175 and 200 mg/m2; Cisplatin 80 mg/m2, i.v., day 1; Etoposide 50 mg/m2, i.v., day 1 and 100 mg/m2 p.o., days 2-3 for the first group, then 80 mg/m2, i.v., day 1 and 160 mg/m2, p.o., days 2-3 for subsequent groups
Trial: 7917734
Drug: 1% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% prilocaine 20 ml (plain)
Trial: 7917734
Drug: 1% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% prilocaine 20 ml (alkalinized)
Trial: 2973665
Drug: Nebulised ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised ipratropium 1 mg
Trial: 2973665
Drug: Nebulised ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised ipratropium 1 mg at 6 am
Trial: 29866475
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly carfilzomib (70 mg/m2)
Trial: 29866475
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly carfilzomib (27 mg/m2)
Trial: 29866475
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly carfilzomib
Trial: 29866475
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly carfilzomib
Trial: 28188155
Drug: Presentation framing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation framing the patient's absolute fracture risk as the chance of having or not having an event, with benefits from osteoporosis treatment in natural frequencies or numbers needed to treat.
Trial: 12665996
Drug: Traditional flow
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional flow triggering (2 l/min)
Trial: 4026908
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg twice daily
Trial: 12167389
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg twice daily
Trial: 10420109
Drug: Lomefloxacin 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 0.3% eye drops twice daily
Trial: 8828727
Drug: Fucidic acid
RxNorm normalized name: Fucidate
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucidic acid 1% eye drops twice daily
Trial: 1594263
Drug: Transdermal clonidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine, 0.3 mg/day
Trial: 6510772
Drug: Liquid monopolar
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid monopolar - Storz (L)
Trial: 31325145
Drug: Perifosine (PRF)
RxNorm normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifosine (PRF) 600 mg loading dose (4 divided doses on day 1) followed by 100 mg daily until disease progression or intolerable toxicity
Trial: 29518077
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term psychodynamic therapy (PDT)
Trial: 29518077
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and Short term psychodynamic therapy (PDT)
Trial: 26539836
Drug: Lidopat(®) 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidopat(®) 5% skin patch
Trial: 26539836
Drug: Placebo vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle patch
Trial: 17376044
Drug: Vitamin K2
RxNorm normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K2 (menatetrenone) at 45 mg per day
Trial: 1954810
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg three times daily for 24 weeks
Trial: 30860552
Drug: High-dose prenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prenatal vitamin D supplementation
Trial: 30860552
Drug: Standard-dose prenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose prenatal vitamin D supplementation
Trial: 27107153
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors as an alternative to tamoxifen with ovarian suppression
Trial: 24521787
Drug: Inhaled hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled hypertonic saline solution (HSS)
Trial: 22284962
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of periconceptional vitamins or supplements that contain folic acid
Trial: 22284962
Drug: Periconceptional vitamins
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periconceptional vitamins or supplements that contain folic acid
Trial: 17588826
Drug: Lovastatin 20-40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20-40 mg/day
Trial: 12422101
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin injections
Trial: 12422101
Drug: Both EPC
RxNorm normalized name: Epclusa
DrugBank: Velpatasvir (DB11613)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both EPC devices and unfractionated heparin injections
Trial: 9854453
Drug: beta-blockers (metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blockers (metoprolol or propranolol)
Trial: 7832192
Drug: rhGM-CSF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM-CSF with prophylactic treatment with vitamin K
Trial: 2170883
Drug: Yohimbine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha 2‐adrenergic antagonist)
Trial: 2170883
Drug: Clonidine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (alpha 2‐adrenergic agonist)
Trial: 326219
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Caffeine (Finimal)
Trial: 31813388
Drug: Drink containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink containing 700 mg of Ca (DAIR)
Trial: 31813388
Drug: Energy-restricted diet
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-restricted diet containing 1200 mg Ca/d
Trial: 31813388
Drug: Drink containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink containing 0 mg of Ca (CONT)
Trial: 30537063
Drug: Topical cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cysteamine cream applied once daily for 2 and 4 months.
Trial: 30537063
Drug: Topical cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cysteamine cream applied biweekly after initial treatment.
Trial: 30537063
Drug: Topical cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cysteamine cream.
Trial: 26116930
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine (LDX) 70 mg
Trial: 26116930
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) 0 mg
Trial: 21830062
Drug: Initial CPAP
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial CPAP treatment in OSAS group
Trial: 17489880
Drug: NPD +
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NPD + L-phenylalanine (7.5 g/day)
Trial: 17489880
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (HPD, 141.3 +/‐ 3.7 g/day)
Trial: 17489880
Drug: Normal-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein diet (NPD, 73.2 +/‐ 2.6 g/day)
Trial: 11413085
Drug: Co-amilozide (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amilozide (hydrochlorothiazide 25 mg and amiloride 2.5 mg)
Trial: 9626118
Drug: Diazoxide (DZ)
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazoxide (DZ) 2 mg/kg BW.day; maximum 200 mg/day, divided into 3 doses for 8 weeks
Trial: 7701041
Drug: Nicotine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0, 2, 4, 8, and 12 micrograms/kg) administered by measured‐dose nasal spray
Trial: 7701041
Drug: Nicotine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (12 micrograms/kg) administered by measured‐dose nasal spray
Trial: 30222788
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous (IV) and intra-articular (IA) administration of tranexamic acid (TXA)
Trial: 30222788
Drug: IV only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV only administration of tranexamic acid (TXA)
Trial: 30222788
Drug: Combined IV
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined IV and IA administration of TXA
Trial: 30222788
Drug: IV only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV only administration of TXA
Trial: 23436914
Drug: Atorvastatin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin for 36 months
Trial: 22512878
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal amino acid solution in the same quantity for 7 days)
Trial: 20227716
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (15 mg zinc + 60 mg iron + 250 microg folic acid)
Trial: 20227716
Drug: Placebo (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (60 mg iron + 250 microg folic acid)
Trial: 15795200
Drug: Ultrasound-guided needling
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided needling followed by high-energy shock-wave therapy
Trial: 15795200
Drug: Shock-wave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock-wave therapy alone
Trial: 12493263
Drug: Fosmidomycin for
RxNorm normalized name: fosfomycin Granules for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin for 5 days (1.2 g every 8 h)
Trial: 12493263
Drug: Fosmidomycin for
RxNorm normalized name: fosfomycin Granules for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin for 4 days (1.2 g every 8 h)
Trial: 12493263
Drug: Fosmidomycin for
RxNorm normalized name: fosfomycin Granules for Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmidomycin for 3 days (1.2 g every 8 h)
Trial: 10909495
Drug: Program I
RxNorm normalized name: Program Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program I (individual, motivating instructions of oral cavity hygiene, 10 meetings)
Trial: 2387655
Drug: SMS 201-995
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS 201-995 (10-hour i.v. infusion at a rate of 8 g/min)
Trial: 30900268
Drug: Energy-enriched formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-enriched formula (EE-formula) (1 kcal/mL)
Trial: 30900268
Drug: Normocaloric formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normocaloric formula (0.67 kcal/mL)
Trial: 31084562
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) applied three times a week for 4 weeks
Trial: 31084562
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) applied once a week for 4 weeks
Trial: 27813150
Drug: Cariex® spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariex® spray combined with non-surgical periodontal therapy
Trial: 27813150
Drug: Cariex® spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariex® spray alone
Trial: 27813150
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy alone
Trial: 25530011
Drug: Boysenberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boysenberry beverage (750 mg polyphenols)
Trial: 25530011
Drug: Apple fiber
RxNorm normalized name: Acacia/Apple Fiber/Apple Pectin/Astragalus Root/Barberry Bark/Beet Root/Burdock Root/Capsicum/Ginger Root/Milk Thistle Seed Extract/Peppermint Leaf Extract/Prune/Psyllium Husk/Watercress Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple fiber beverage (7.5 g dietary fiber)
Trial: 25530011
Drug: Boysenberry plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boysenberry plus apple fiber beverage (750 mg polyphenols plus 7.5 g dietary fiber)
Trial: 25146288
Drug: No vaccine
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No vaccine (Control)
Trial: 22520095
Drug: CTC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC group (CT cisternography considered before treatment)